Pharmaxis (ASX:PXS) today announced that its second pivotal Phase 3 clinical trial of Bronchitol for the treatment of cystic fibrosis has now passed its recruitment target of 300 subjects. The first efficacy data from the trial is expected to be available during the first half of 2010.

Download Media Release